Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Nurix Therapeutics ( (NRIX) ).
On October 22, 2025, Nurix Therapeutics announced an underwriting agreement to offer 24,485,799 shares of common stock at $10.21 per share, expecting gross proceeds of $250 million. The net proceeds will primarily fund clinical development of drug candidates, including bexobrutideg for chronic lymphocytic leukemia, and expand research and development activities. The offering, involving both new and existing investors, is set to close on October 23, 2025, subject to customary conditions, and is part of a shelf registration filed with the SEC.
The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.
Spark’s Take on NRIX Stock
According to Spark, TipRanks’ AI Analyst, NRIX is a Neutral.
Nurix Therapeutics’ overall stock score is primarily influenced by its financial performance and valuation challenges. While the company benefits from strong gross margins and low leverage, its profitability issues and negative P/E ratio weigh heavily on the score. Technical analysis provides a slightly positive outlook, but the stock’s position below key moving averages suggests caution.
To see Spark’s full report on NRIX stock, click here.
More about Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California, specializing in the discovery, development, and commercialization of targeted protein degradation medicines. These medicines are designed to improve treatment options for patients with cancer and autoimmune diseases. The company’s pipeline includes degraders of Bruton’s tyrosine kinase for chronic lymphocytic leukemia and potential autoimmune indications, as well as inhibitors of Casitas B-lineage lymphoma proto-oncogene B. Nurix collaborates with major pharmaceutical companies like Sanofi, Gilead Sciences, and Pfizer, and utilizes an AI-integrated discovery engine to advance its drug discovery efforts.
Average Trading Volume: 952,307
Technical Sentiment Signal: Hold
Current Market Cap: $798.8M
For an in-depth examination of NRIX stock, go to TipRanks’ Overview page.